Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and tolerability of Lyndra's long-acting oral risperidone (LYN-005) in schizophrenia or schizoaffective disorder has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperidone (LYN-005, long-acting formulation) (risperidone)

Snippet

Sponsor: Lyndra Inc. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: WITHDRAWN